Sec Form 4 Filing - AFEYAN NOUBAR @ BG Medicine, Inc. - 2015-07-27

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person AFEYAN NOUBAR 2. Issuer Name and Ticker or Trading Symbol BG Medicine, Inc. [ BGMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O FLAGSHIP VENTURES, ONE MEMORIAL DRIVE, 7TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 07/27/2015 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock ( 1 ) 07/27/2015 X( 2 ) 53,857 A $ 0.14 766,720 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 2 ) 3,390 D $ 2.27 ( 4 ) 763,330 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 X( 5 ) 4,205 A $ 0.14 767,535 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 5 ) 265 D $ 2.27 ( 4 ) 767,270 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 X( 6 ) 4,205 A $ 0.14 771,475 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 6 ) 265 D $ 2.27 ( 4 ) 771,210 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 X( 7 ) 4,205 A $ 0.14 775,415 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 7 ) 265 D $ 2.27 ( 4 ) 775,150 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 X( 8 ) 4,205 A $ 0.14 779,355 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 8 ) 265 D $ 2.27 ( 4 ) 779,090 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 X( 9 ) 8,410 A $ 0.14 787,500 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 07/27/2015 S( 9 ) 530 D $ 2.27 ( 4 ) 786,970 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Common Stock ( 1 ) 43,930 D Common Stock ( 1 ) 53,754 I Held by AGTC Advisors Fund, L.P. ( 3 ) Common Stock ( 1 ) 2,508 I Held by Atlast LP ( 10 ) Common Stock ( 1 ) 441,072 I Held by Flagship Ventures Fund 2007, L.P. ( 11 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 53,857 ( 12 ) 07/28/2015 Common Stock 53,857 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 4,205 ( 12 ) 09/08/2015 Common Stock 4,205 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 4,205 ( 12 ) 09/28/2015 Common Stock 4,205 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 4,205 ( 12 ) 11/14/2015 Common Stock 4,205 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 4,205 ( 12 ) 12/15/2015 Common Stock 4,205 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 ) Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 8,410 ( 12 ) 03/10/2016 Common Stock 8,410 $ 0 0 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other AFEYAN NOUBAR C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X X Flagship Ventures Management, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X NewcoGen Group, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X Applied Genomic Technology Capital Fund LP C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X AGTC Partners, L.P. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X Signatures /s/ Noubar B. Afeyan, Ph.D. 07/29/2015 Signature of Reporting Person Date /s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for Flagship Ventures Management, Inc. 07/29/2015 Signature of Reporting Person Date /s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for NewcoGen Group, Inc. 07/29/2015 Signature of Reporting Person Date /s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for Applied Genomic Technology Capital Fund, L.P. 07/29/2015 Signature of Reporting Person Date /s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for AGTC Partners, L.P. 07/29/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Share and price per share amounts have been adjusted to reflect a 1-for-4 reverse split of the Issuer's common stock on July 8, 2015. ( 2 )On July 27, 2015, Applied Genomic Technology Capital Fund, L.P. ("AGTCF") exercised warrants to purchase 53,857 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 3,390 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 50,467 shares. ( 3 )NewcoGen Group, Inc. ("NG") is the general partner of AGTC Partners, L.P., which is the general partner of AGTCF and AGTC Advisors Fund, L.P. ("AGTCA", and together with AGTCF, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar B. Afeyan, Ph.D. is the director of Flagship and may be deemed to beneficially own the securities held by the AGTC Funds. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 4 )The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date. ( 5 )On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares. ( 6 )On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares. ( 7 )On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares. ( 8 )On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares. ( 9 )On July 27, 2015, AGTCF exercised warrants to purchase 8,410 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 530 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 7,880 shares. ( 10 )Noubar B. Afeyan, Ph.D. is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 11 )Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Dr. Afeyan and Mr. Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 12 )This warrant is immediately exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.